Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A systematic review finds Incomplete excision rates for basal cell carcinoma range from 4.7% to 20.4% against recommended guidelines of 5%.

A doctor examines moles on a woman's back

Nonmelanoma skin cancer (NMSC), either basal cell carcinoma (BCC) or squamous cell carcinoma (SCC), is the commonest cancer worldwide. The usual treatment is surgical excision, where a cut is made around the malignancy including an area of normal tissue, removing all of the skin cancer cells and curing the patient.

Guidelines published by the British Association of Dermatologists quote a 5% incomplete excision rate, enabling practitioners to advise patients on possible outcomes and providing a benchmark for audit targets.

However, in a new study published in the British Journal of Dermatology, Abhilash Jain, Associate Professor of Plastic and Hand Surgery at NDORMS, University of Oxford reveals that current guidelines underestimate the rates of incomplete excision.

“We found that the proportion of incomplete excisions is actually 11% for basal cell carcinomas, more than double the current guidelines,” said Jain. “That’s important because as practitioners, globally, we need to be able to give our patients information about possible chances of failure. A one in 20 rate is significantly different to a one in ten.”

Incomplete excisions may require further surgery or increased surveillance, which burdens patients and healthcare systems, increasing the costs and morbidity of skin cancer care.

For the study, a trainee group of young plastic surgeons carried out the most comprehensive review to date of primary clinical studies. They analysed 3477 citations in 100 separate studies with a total of 106,832 BCC and 21,569 SCC excisions included. Importantly, Mohs micrographic surgeries were excluded from the analysis as their near 100% success rate obscures the real figures.

Variations in the incomplete excision rate ranged from 4.7% to 20.4%. Differences were found by operating specialty (dermatologists, plastic surgeons, general practitioners, ophthalmology etc.). 

Abhilash said: “The variance can be explained by many factors including the degree of surgical training within the specialty and the complexity of the surgery. We would argue that a 5% blanket rate is not correct but that excision by specialists may reduce treatment failure. Our recommendation is that guidelines are refined to take account of the type of tumour, and to the specialism of surgeons performing the procedure. This will give us a better idea of what we tell our patients, and also how we audit our outcomes.

A forthcoming audit of current plastic surgery outcomes in the UK will provide the evidence to support amendments to update current guidelines,” he concluded.

Similar stories

Yoshi Itoh wins the International Dupuytren Award 2022

Yoshi Itoh, Associate Professor and Principal Investigator Cell Migration Group at the Kennedy Institute has been awarded the International Dupuytren Award 2022.

Taking a break from immune-suppressing medicines doubles the antibody response to COVID-19 booster vaccination

The Oxford Clinical Trials Research Unit (OCTRU) at NDORMS played a key role in the VROOM study which found that pausing immune-suppressing medicines such as methotrexate can increase the response to COVID-19 booster jabs.

Ten Years of Athena Swan in the Medical Sciences Division

2022 marks ten years since the first Athena Swan Bronze applications from the Medical Sciences Division. Ten years later, and all 16 departments in the Division have achieved a Silver Award. We look at NDORMS’ Athena Swan journey.

NDORMS researchers awarded Associate Professor title

The University of Oxford has awarded the title of Associate Professor to Adam Cribbs and Luke Jostins.

Oxford's largest ever study into varicose veins shows need for surgery is linked to genetics

A new international study by Oxford researchers published in Nature Communications, establishes for the first time a critical genetic risk score to predict the likelihood of patients suffering with varicose veins to require surgery, as well as pointing the way towards potential new therapies.

Reflecting on the role of Clinical Director of Trauma and Orthopaedics

In 2021 Professor Andrew Price was appointed Clinical Director of Trauma and Orthopaedics at the Oxford University Hospitals NHS Foundation Trust. After 9 months in post, we find out what the challenges are and what he’s been able to bring to the role.